title: [Therapeutic efficacy of ursodeoxycholic acid in persistent gallbladder lithiasis and persistent biliary sludge: preliminary results of a multicenter experience].
abstract: A prospective and multicenter study was performed to determine the efficacy and tolerance of ursodeoxycholic acid (UDCA) in the treatment of gallstones and biliary sludge. Criteria for entry into the trial were radiolucent gallbladder stones; until 20 mm of size and visualization of the gallbladder by oral cholecystography. Too were treatment the patients with persistent biliary sludge (PBS) defined by the persistence of the biliary sludge in two consecutive echography along three months. Without severe gallbladder disease. Then daily UDCA doses of 600 mg were suminstred divided in two postprandial times for a six months period. The control to the treatment were: basal ultrasonography (US) of the gallbladder and by follow-up gallbladder US for six months; clinical examination every month and cholecystography before and after the treatment. Of 110 admitted patients, 19 (17%) stopped the treatment for no-medical reasons and 91 (83%) arrived to the and point. After six months of treatment, complete dissolution was observed in 50% of the patients (46/91), partial in the 43% (39/91) and failed the treatment in 6.5% (6/91) who presented high density stones for computed tomography, CT (greater than 60 UH). According to pattern of lithiasis dissolution was complete in 100% (22/22) of the patients with PBS; 71.4% (10/14) in microlithiasis and 25% (14/55) in macrolithiasis. Minor adverse effects were acidism in the 7.7% (7/91) and diarrhea in the 1.1% (1/91). In the other hand, one patient presented acute pancreatitis (1/91; 1.1%), it must be discussed if was a complication of the lithiasis or an therapeutic effect. The UDCA was a safe and effective treatment without lethality in PBS and in microlithiasis while in case of macrolithiasis must be standardized response criterion, for example density stones for CT.
authors.affiliation: Hospital Eva Perón.
authors.forename: C
authors.initials: C
authors.lastname: Guma
authors.forename: L
authors.initials: L
authors.lastname: Viola
authors.forename: C
authors.initials: C
authors.lastname: Apestegui
authors.forename: L
authors.initials: L
authors.lastname: Pinchuk
authors.forename: J
authors.initials: J
authors.lastname: Groppa
authors.forename: J
authors.initials: J
authors.lastname: Michelini
authors.forename: B
authors.initials: B
authors.lastname: Martínez
authors.forename: R
authors.initials: R
authors.lastname: Bolaños
authors.forename: L
authors.initials: L
authors.lastname: Toselli
mesh_terms: D000328:Adult; D002765:Cholecystography; D002769:Cholelithiasis / Q000188:drug therapy*; D002985:Clinical Protocols; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D014580:Ursodeoxycholic Acid